BAX Baxter International
- Price as of: Dec 19, 10:23 PM EST
- Medical instruments & supplies
BAX Stock Dividend DataAdd BAX to Watchlist
BAX Daily Snapshot
- Quote Time:
- Dec 19, 10:23 PM
- Today's Volume:
- Open Price:
- Day's Range:
- $73.37 - $74.77
- Previous Close:
- 52 Week Low / High:
- $66.34 - $77.31
- Percent Off 52 Week High:
BAX Dividend Growth History
Last 5 Yrs
Last 3 Yrs
|Reveal More Dividend Growth History for BAX||17.6%||22.3%||6 years|
BAX Dividend History
|Payout Amount||Declared Date||Ex-Dividend Date||Record Date||Pay Date ▼||Qualified Dividend?||Payout Type||Frequency|
BAX Company Profile
Baxter (BAX) assists healthcare professionals and their patients with the treatment of complex medical conditions, including hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other medical conditions. Baxter’s products are subject to extensive regulations by government agencies. Baxter International was founded in 1931 and is based in Deerfield, Illinois. Baxter is largely affected by its ability to successfully introduce new products on a consistent basis, as well as the strength of patent protection for its products. Baxter has been paying dividends since 1980, and has increased them consecutively annually since 2007. Baxter pays its dividends quarterly.
Baxter International News
Dec 11, 2014Widely regarded as the father of value investing, and perhaps better known as Warren Buffett's teacher, Benjamin Graham famously said the following...
Today's Pre-Market Earnings: Baker Hughes Incorporated, Danaher Corporation, UnitedHealth Group Inc., More (BHI, DHR, UNH, More)Jul 17, 2014Before the opening bell on Thursday, a number of big name, dividend paying companies announced their quarterly earnings. Below, we look at these...
May 5, 2014U.S. equities edged slightly higher on Monday, as investors digested mixed economic reports. Also during today's session, four companies raised...
Mar 27, 2014These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Signet Jewelers...
Mar 27, 2014Baxter International (BAX) announced early on Thursday morning that it would be splitting into two publicly-traded, independent, global,...
Tuesday Analyst Moves: Johnson & Johnson, Yum! Brands, Inc., Target Corporation, More (JNJ, YUM, TGT, More)Jan 7, 2014Before Tuesday's opening bell, a number of big name dividend stocks were the subject of analyst moves. Below, we highlight the important analyst...
Baxter Int'l Q3 Profit Slides on Acquisition Costs; Adjusted EPS Matches Estimates, But Revenue Misses (BAX)Oct 17, 2013Before the bell on Thursday, Baxter International Inc. (BAX) , a maker of medical products, reported a 7% year-over-year decline in third quarter profits, mostly due to the impact of charges related to its acquisition of Gambro. Excluding these charges, Baxter's third quarter earnings were in-line with Wall Street analysts' views. The Deerfield, Illinois-based company posted a third quarter net income of $544 million, or 99 cents per share, down from the $583 million, or $1.06 per share, earned in the same period a year ago. This decline in third quarter earnings was mostly due to special one-time charges totaling 20 cents per share related to Baxter's $3.9 billion acquisition of medical tech specialist Gambro AB. On an adjusted basis, excluding the special items like the one mentioned above, Baxter's third quarter earnings came in at $655 million, or $1.19 per share, up from $628 million, or $1.14 per share, the year before. According to analysts polled by Thomson Reuters, the company was expected to earn $1.19 per share in the third quarter. Baxter's net sales came in at $3.774 billion in the third quarter, up about 9% from the $3.477 billion in revenues posted in the third quarter of 2012. On average, analysts were expecting the company to see $3.81 billion in revenues, however. Looking ahead to the fourth quarter, the company sees earnings between $1.24 and $1.26 per share, with sales growth between 14% and 15%. Analysts expect the company to earn $1.26 per share on revenues of $4.31 billion in the fourth quarter. For the full year, Baxter sees earnings coming in between $4.65 and $4.67 per share on a sales growth of about 7%. Analysts expect the company to earn $4.67 per share on revenues of $15.24 billion in fiscal 2013. Baxter shares were down $1.56, or 2.31%, during pre-market trading on Thursday. The stock is up 1.35% year-to-date.Expand to read the full story
Oct 2, 2013These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Mosaic Co. (MOS) ...
Credit Suisse Downgrades Baxter International to "Neutral," But Still Sees 11% Upside (BAX)Oct 2, 2013Because the outlook for the hemophilia market remains uncertain, analysts at Credit Suisse downgraded healthcare products manufacturer Baxter International Inc. (BAX) early on Wednesday. The analysts downgraded BAX from "Outperform" to "Neutral" and see shares reaching $73. This price target suggests an 11% upside to the stock's Tuesday closing price of $65.58. Baxter shares were down 62 cents, or 0.95%, during pre-market trading on Wednesday. The stock is up 1.62% year-to-date.Expand to read the full story
The Bottom LineShares of Baxter International (BAX) offer a dividend yield of 2.99% based on Tuesday's closing price of $65.58 and the company's annualized dividend payout of $1.96 per share. Baxter International Inc. (BAX) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
Baxter Completes Acquisition of Gambro (BAX)Sep 6, 2013On Friday, healthcare company Baxter International Inc. (BAX) announced that it has finalized its acquisition of medical technology company Gambro AB. The acquisition will help Baxter's long term growth in the healthcare industry and will expand its product and therapies portfolio. Baxter will also help grow Gambro's international exposure by expanding into Latin American and Asia Pacific. The deal was worth about $3.9 billion and will be included in BAX's third quarter and full year results. Robert L. Parkinson, Jr., chairman and chief executive officer of Baxter commented: "The combination of these two respected renal leaders - Baxter and Gambro - will enable Baxter to better serve healthcare providers and patients through a collective offering of innovative renal products and therapies." "Together, we will advance the state of dialysis care for patients with kidney disease worldwide." Baxter International shares were mostly flat during pre-market trading Friday. The stock is up 5% YTD. The Bottom Line Shares of Baxter International Inc. (BAX) have a 2.81% yield based on Thursday's closing price of $69.78. Baxter International Inc. (BAX) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.Expand to read the full story